Double filtration plasmapheresis benefits myasthenia gravis patients through an immunomodulatory action

Vincent, 2002, Unravelling the pathogenesis of myasthenia gravis, Nat Rev Immunol, 2, 797, 10.1038/nri916

Meriggioli, 2009, Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity, Lancet Neurol, 8, 475, 10.1016/S1474-4422(09)70063-8

Vincent, 2003, Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets, Lancet Neurol, 2, 99, 10.1016/S1474-4422(03)00306-5

Romi, 2005, Myasthenia gravis: clinical, immunological, and therapeutic advances, Acta Neurol Scand, 111, 134, 10.1111/j.1600-0404.2005.00374.x

Milani, 2003, T cells and cytokines in the pathogenesis of acquired myasthenia gravis, Ann N Y Acad Sci, 998, 284, 10.1196/annals.1254.032

Xu, 2001, Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells, Cell Immunol, 208, 107, 10.1006/cimm.2001.1777

Aarli, 2003, Role of cytokines in neurological disorders, Curr Med Chem, 10, 1931, 10.2174/0929867033456918

Zhang, 2009, The role of FoxP3+CD4+CD25hi Tregs in the pathogenesis of myasthenia gravis, Immunol Lett, 122, 52, 10.1016/j.imlet.2008.11.015

Yeh, 2009, Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis, Eur J Neurol, 16, 1318, 10.1111/j.1468-1331.2009.02729.x

Qureshi, 2000, Plasma exchange for treatment of myasthenia gravis: pathophysiologic basis and clinical experience, Ther Apher, 4, 280, 10.1046/j.1526-0968.2000.004004280.x

Goto, 2001, Plasmapheresis affects T helper type-1/T helper type-2 balance of circulating peripheral lymphocytes, Ther Apher, 5, 494, 10.1046/j.1526-0968.2001.00386.x

Yeh, 2007, Changes in the lymphocyte subset after double-filtration plasmapheresis, Am J Clin Pathol, 128, 940, 10.1309/L0DG8YU2WE5DV58H

Jaretzki, 2000, Myasthenia gravis: recommendations for clinical research standards, Ann Thorac Surg, 70, 327, 10.1016/S0003-4975(00)01595-2

Skeie, 1995, Titin antibodies in patients with late onset myasthenia gravis: clinical correlations, Autoimmunity, 20, 99, 10.3109/08916939509001933

Lu, 1991, Anti-presynaptic membrane receptor antibodies in myasthenia gravis, J Neurol Sci, 102, 39, 10.1016/0022-510X(91)90091-K

Xiuyun, 1997, A clinical absolute and relative score system for myasthenia gravis, Chin J Neurol, 30, 87

Schröder, 2009, Plasmapheresis for neurological disorders, Expert Rev Neurother, 9, 1331, 10.1586/ern.09.81

Cortese, 2011, Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Neurology, 76, 294, 10.1212/WNL.0b013e318207b1f6

Liu, 2010, Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis, Ther Apher Dial, 14, 153, 10.1111/j.1744-9987.2009.00751.x

Skeie, 2006, Titin and ryanodine receptor antibodies in myasthenia gravis, Acta Neurol Scand. Suppl, 183, 19, 10.1111/j.1600-0404.2006.00608.x

Furukawa, 2008, Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis, J Neuroimmunol, 195, 108, 10.1016/j.jneuroim.2007.12.008

Hubbard, 2000, Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades, Free Radic Biol Med, 28, 1379, 10.1016/S0891-5849(00)00223-9

Long, 2011, ICAM-1: getting a grip on leukocyte adhesion, J Immunol, 186, 5021, 10.4049/jimmunol.1100646

Holland, 1997, Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B cell lymphoma line. The activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway, J Biol Chem, 272, 9108, 10.1074/jbc.272.14.9108

Mu, 2009, Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis, Immunology, 128, e826, 10.1111/j.1365-2567.2009.03089.x

Masuda, 2010, Clinical implications of the type 1/type 2 balance of helper T cells and P-glycoprotein function in peripheral T lymphocytes of myasthenia gravis patients, Eur J Pharmacol, 627, 325, 10.1016/j.ejphar.2009.10.040

Josefowicz, 2012, Regulatory T cells: mechanisms of differentiation and function, Annu Rev Immunol, 30, 531, 10.1146/annurev.immunol.25.022106.141623

Jamshidian, 2012, Can plasma exchange therapy induce regulatory T lymphocytes in multiple sclerosis patients?, Clin Exp Immunol, 168, 75, 10.1111/j.1365-2249.2011.04547.x

Bilate, 2012, Induced CD4+Foxp3+ regulatory T cells in immune tolerance, Annu Rev Immunol, 30, 733, 10.1146/annurev-immunol-020711-075043

Sewgobind, 2010, The calcineurin inhibitor tacrolimus allows the induction of functional CD4CD25 regulatory T cells by rabbit anti-thymocyte globulins, Clin Exp Immunol, 161, 364, 10.1111/j.1365-2249.2010.04183.x